Industry
Biotechnology
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Loading...
Open
16.95
Mkt cap
444M
Volume
515K
High
17.00
P/E Ratio
-79.38
52-wk high
17.00
Low
16.33
Div yield
N/A
52-wk low
3.03
Portfolio Pulse from
January 24, 2025 | 10:30 am
Portfolio Pulse from
January 03, 2025 | 12:00 pm
Portfolio Pulse from
December 20, 2024 | 12:00 pm
Portfolio Pulse from
November 18, 2024 | 3:00 pm
Portfolio Pulse from
November 13, 2024 | 1:15 am
Portfolio Pulse from
November 12, 2024 | 9:15 pm
Portfolio Pulse from
November 06, 2024 | 9:45 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 2:38 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.